Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

14 Dec 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Nuclear Receptors and Signaling

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 22197375
DOI: 10.1016/j.jmb.2011.11.047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's DiseasePMID 22197375Read ↗

Structure of Crenezumab Complex with Aβ Shows Loss of β-HairpinSemantic proximity Read ↗

Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesSemantic proximity Read ↗

Decoding the Roles of Amyloid-β (1–42)’s Key Oligomerization Domains toward Designing Epitope-Specific Aggregation InhibitorsSemantic proximity Read ↗

Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation.Semantic proximity Read ↗

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.Semantic proximity Read ↗

Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s diseaseSemantic proximity Read ↗

Engineering a Dimeric Single-Domain Antibody for Improved Detection and neutralization of Amyloid-β OligomersSemantic proximity Read ↗

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.Semantic proximity Read ↗

Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity.Semantic proximity Read ↗

<i>In Silico</i> Design of APOE ɛ4 Interaction Inhibitor Peptides for Alzheimer’s DiseaseSemantic proximity Read ↗

Rational design of antibodies targeting specific epitopes within intrinsically disordered proteinsSemantic proximity Read ↗

A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.